



IFW
Attorney Docket No. 11520.0333

I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on September 13, 2004

Pam Assad

Name

Signature

September 13, 2004

Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Niles et al.

Filed: January 2, 2004

Serial No. 10/750,939

For: Novel Inhibitors of Poxvirus Replication

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants wish to make of record the following references under the provisions of 37 C.F.R. §1.97 (legible copies are enclosed).

Bromouridine Triphosphate Inhibits Transcription Termination and mRNA Release by Vaccinia Virions	Shuman et al.
Factor-dependent Release of Nascent RNA by Ternary Complexes of Vaccinia RNA Polymerase	Deng et al.


Please see attached form PTO/SB/08A for a listing of the references.

It is believed no fee is due with this *Information Disclosure Statement*. If a fee is due, please charge deposit account number 08-2442.

The person making this statement is the patent attorney who signs below on the basis of the information supplied by the inventor, and as the attorney associated with the filing and prosecution of this application (37 CFR 1.56(a)).

Respectfully submitted,

By: _____


John D. Lopinski
Reg. No. 50,846

HODGSON RUSS LLP
One M & T Plaza, Suite 2000
Buffalo, New York 14203-2391
Date: September 13, 2004

Approved for use through 10/31/2002, OMB 0651-0031

(Use as many sheets as necessary)

Application Number	10/750,939
Filing Date	January 2, 2004
First Named Inventor	Niles et al.
Group Art Unit	
Examiner Name	

Sheet	1	of	1	Attorney Docket Number	11520.0333
-------	---	----	---	------------------------	------------

[illegible]

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.** Send to the Assistant Commissioner for Patents, Washington, DC 20231.